Data from: CRISPR-Cas9 mediated CD133 knockout inhibits colon cancer invasion through reduced epithelial-mesenchymal transition

We previously reported that CD133, as a putative cancer stem cell marker,
plays an important role in cell proliferation and invasion in colon
cancer. To understand the role of CD133 expression in colon cancer, we
evaluated the inhibitory effect of CD133 in colon cancer cells. In this
study, we generated CD133knockout colon cancer cells (LoVo) using the
CRISPR-Cas9 gene editing system. CD133+ colon cancer cells (LoVo) were
infected with the lentiviral vector carrying CD133 gRNA and purified cell
by culturing single cell colonies. CD133knockout cells was validated by
western blot and flow cytometry analysis. In functional study, we observed
a significant reduction in cell proliferation and colony formation in
CRISPR-Cas9 mediated CD133 knockout cells in compare with control (P
< 0.001). We also found the anticancer effect of stattic was
dependent on CD133 expression in colon cancer cells. Although
CD133knockout cells could not completely block the tumorigenic property,
they showed remarkable inhibitory effects on the ability of cell migration
and invasion (P < 0.001). In addition, we examined the epithelial
mesenchymal transition (EMT)-related protein expression by western blot.
The result clearly showed a loss of vimentin expression in CD133knockout
cells. Therefore, CRISPR-Cas9 mediated CD133knockout can be an effective
treatment modality for CD133+ colon cancer through reducing the
characteristics of cancer stem cells.